GSK, Harvard collaborate on stem-cell drugs

NEW YORK GlaxoSmithKline and Harvard University will collaborate to develop treatments for cardiovascular disease, cancer, diabetes and others through stem-cell research.

GSK announced Thursday that it would donate $25 million to Harvard’s Stem Cell Institute and hospitals associated with it. The move is meant to address GSK’s declining output of new drugs.

Under the collaboration, GSK and Harvard will exchange scientists and establish a steering committee to govern the operation.